237 related articles for article (PubMed ID: 33999485)
1. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
[TBL] [Abstract][Full Text] [Related]
2. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Quinones L; Rosenheck R
Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898
[TBL] [Abstract][Full Text] [Related]
5. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
6. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
7. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
8. Barriers to retention in medications for opioid use disorder treatment in real-world practice.
Villamil VI; Underwood N; Cremer LJ; Rooks-Peck CR; Jiang X; Guy GP
J Subst Use Addict Treat; 2024 May; 160():209310. PubMed ID: 38331319
[TBL] [Abstract][Full Text] [Related]
9. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
[TBL] [Abstract][Full Text] [Related]
10. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Camenga DR; Colon-Rivera HA; Muvvala SB
J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374
[TBL] [Abstract][Full Text] [Related]
11. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
13. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
14. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
Benville JR; Compton P; Giordano NA; Cheatle MD
Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
[TBL] [Abstract][Full Text] [Related]
15. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
[TBL] [Abstract][Full Text] [Related]
16. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.
Hickman M; Steer C; Tilling K; Lim AG; Marsden J; Millar T; Strang J; Telfer M; Vickerman P; Macleod J
Addiction; 2018 Aug; 113(8):1461-1476. PubMed ID: 29672985
[TBL] [Abstract][Full Text] [Related]
17. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
18. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
[TBL] [Abstract][Full Text] [Related]
19. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder.
Robin AM; Hersh AR; John C; Caughey AB
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):4918-4926. PubMed ID: 33455473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
